GlassScriptPhysician profile
Joyce P Peterson
NPI 1588005128
$4,860.59
in general payments reported to CMS, 2019-2025
26 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $784 · 2022: $1,048 · 2023: $854 · 2024: $1,076 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.85 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $574.47 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $456.96 | 2021-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $388.06 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $379.09 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $364.38 | 2021-2025 | Veltassa |
| Amgen INC. | $350.29 | 2022-2025 | Tavneos, Parsabiv, Krystexxa |
| Fresenius USA Marketing, INC. | $345.32 | 2021-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $338.26 | 2021-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $334.83 | 2021-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $248.06 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $207.38 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $175.35 | 2024-2025 | |
| Travere Therapeutics, INC. | $158.58 | 2022-2024 | |
| Novo Nordisk INC | $135.33 | 2025 | Wegovy, Ozempic |
| Ardelyx, INC. | $74.73 | 2024-2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $43.96 | 2023 | Krystexxa |
| Cormedix INC. | $41.10 | 2024 | Defencath |
| Lilly USA, LLC | $39.67 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $35.99 | 2023 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $35.81 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $31.47 | 2022 | |
| Daiichi Sankyo INC. | $24.01 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $23.65 | 2021 | |
| Scpharmaceuticals INC. | $20.29 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.95 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.